Nature Reviews Nephrology最新文献_第10页

Indigenous kidney health outcomes will not improve without multilevel interventions 如果没有多层次的干预措施，本地肾脏健康状况不会得到改善

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-22 DOI: 10.1038/s41581-025-01046-w

引用次数: 0

Strengthening kidney care through evidence-informed participatory policymaking 通过循证参与式决策加强肾脏护理。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-21 DOI: 10.1038/s41581-025-01032-2

Neha Purohit, Shankar Prinja

引用次数: 0

Health risks of oil and gas development 石油和天然气开发的健康风险。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-20 DOI: 10.1038/s41581-026-01050-8

Melissa R. Haswell, Javier Cortes-Ramirez, Louise G. Woodward

引用次数: 0

Environmentally sustainable kidney care in low- and middle-income countries 中低收入国家环境可持续的肾脏护理。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-20 DOI: 10.1038/s41581-026-01051-7

Abdou Niang, Ahmed Tall Lemrabott

引用次数: 0

Disentangling the role of environmental factors in the CKDu epidemic 解开CKDu流行中环境因素的作用。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-19 DOI: 10.1038/s41581-026-01054-4

Nicholas J. Osborne

引用次数: 0

Sustainable AI in medicine: balancing benefits and environmental costs 医疗领域的可持续人工智能：平衡效益和环境成本。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-15 DOI: 10.1038/s41581-026-01047-3

Nikolas E. J. Schmitz, Cristina Richie, Raghavendra Selvan, Loïc Lannelongue, Ariel Dora Stern, Nick Schneider, Joe Lennerz, Blanca Iciar Indave Ruiz, Martin Strauch, Peter Boor

引用次数: 0

Climate change and AKI: heat, hazards and health-system readiness 气候变化和AKI：热、危害和卫生系统准备。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-14 DOI: 10.1038/s41581-026-01048-2

Rolando Claure-Del Granado, Nuttha Lumlertgul

引用次数: 0

Environmental stewardship and health systems: Indigenous-centred reflections 环境管理和卫生系统：以土著为中心的思考。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-14 DOI: 10.1038/s41581-026-01049-1

Nicole Redvers, Carol Zavaleta-Cortijo

引用次数: 0

Next-generation therapeutics for diabetic kidney disease 糖尿病肾病的新一代治疗方法

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-12 DOI: 10.1038/s41581-025-01042-0

Tae Won Yi, Vikas S. Sridhar, Jennifer Scott, Massimo Nardone, David Cherney

{"title":"Next-generation therapeutics for diabetic kidney disease","authors":"Tae Won Yi, Vikas S. Sridhar, Jennifer Scott, Massimo Nardone, David Cherney","doi":"10.1038/s41581-025-01042-0","DOIUrl":"10.1038/s41581-025-01042-0","url":null,"abstract":"Diabetes mellitus is the leading cause of chronic kidney disease and kidney failure worldwide, and diabetic kidney disease (DKD) is associated with excess cardiovascular and all-cause mortality. The pathophysiology of DKD is complex and multifactorial, characterized by physiologically redundant haemodynamic, metabolic and inflammatory pathways that promote maladaptive renal remodelling and accelerate disease progression. Current management of DKD centres around four key pillars of guideline-directed medical therapy (GDMT): renin–angiotensin–aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, non-steroidal mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists. These therapies are increasingly used in combination for cardiorenal protection in DKD. However, substantial residual cardiorenal risk persists even among patients receiving optimal GDMT. Next-generation therapies for DKD that are currently in development include various incretin-based therapies, endothelin receptor antagonists, aldosterone synthase inhibitors, soluble guanylate cyclase agonists and anti-inflammatory agents. These therapies are expected to complement current GDMT and further improve kidney and cardiovascular outcomes in patients with DKD. In this Review, the authors discuss guideline-directed medical therapy for diabetic kidney disease and the evolving clinical evidence for next-generation therapies, including incretin-based therapies, endothelin receptor antagonists, aldosterone synthase inhibitors, soluble guanylate cyclase agonists and anti-inflammatory therapies.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 5","pages":"318-332"},"PeriodicalIF":39.8,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145956060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1受体激动剂和下一代代谢激素治疗慢性肾脏疾病。

IF 39.8 1区医学

Nature Reviews Nephrology Pub Date : 2026-01-08 DOI: 10.1038/s41581-025-01036-y

Radica Z. Alicic, Joshua J. Neumiller, Katherine R. Tuttle

{"title":"GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease","authors":"Radica Z. Alicic, Joshua J. Neumiller, Katherine R. Tuttle","doi":"10.1038/s41581-025-01036-y","DOIUrl":"10.1038/s41581-025-01036-y","url":null,"abstract":"Chronic kidney disease (CKD) remains a major public health problem, with type 2 diabetes and obesity representing key risk factors worldwide. The complex pathophysiology and the metabolic risk factors shared between type 2 diabetes, obesity, CKD and cardiovascular disease have led to the concept of a cardiovascular–kidney–metabolic (CKM) syndrome. The treatment landscape for CKM changed dramatically when agents from several medication classes, originally developed as glucose-lowering therapies, were recognized to reduce the risk of multiple components of CKM syndrome. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic–GLP-1RAs, have evolved from metabolic therapies to agents with either proven or potential protective effects on the kidney and heart. In addition to their potent metabolic actions that reduce hyperglycaemia and body weight, GLP-1RAs also lower the risk of major kidney, cardiovascular and mortality outcomes across broad populations with cardiovascular disease or CKD, with and without diabetes or obesity. GLP-1RAs have been combined with glucose-dependent insulinotropic agonism, as well as glucagon agonism or amylin analogues to further enhance their metabolic benefits. However, kidney and heart protection are not fully explainable by the metabolic actions of these agents. Rather, a growing body of evidence suggests that the systemic and local actions of incretins and metabolic hormones modulate multiple pathways that can promote inflammatory and fibrotic injury. Targeting incretins is emerging as an effective approach to treat cardiovascular–kidney–metabolic syndrome. Here, the authors examine the biological effects of incretins and other metabolic hormones, such as glucagon and amylin, as well as discussing current clinical data demonstrating the organ-protective effects of incretin drugs and their potential underlying mechanisms.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":"22 4","pages":"265-282"},"PeriodicalIF":39.8,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145934473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0